Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported option exercises and share sales on August 10, 2026. He exercised stock options covering 63,605 shares of common stock, including 35,412 shares at an exercise price of $110.49 per share from an award granted August 3, 2021, which is now fully vested, and 28,193 shares at an exercise price of $28.37 per share from an award granted December 13, 2023 that continues to vest over a three-year period. Freeman then sold 63,605 shares of common stock in open-market transactions at weighted average prices per share ranging from approximately $167.12 to $170.67, with the exact breakdown of shares sold at each price available upon request as noted in the footnotes.
Guardant Health, Inc. shareholder Chris Freeman plans to resell up to 63,605 common shares through Charles Schwab & Co., Inc., with an indicated aggregate market value of $10,786,111.00. The sale is linked to an employee stock option exercise using a broker payment for a cashless exercise on 08/10/2026.
The disclosure also notes a prior sale on 05/22/2026 of 24,406 Guardant Health shares for aggregate proceeds of $2,896,361.00 over the preceding three months.
Guardant Health director Manuel Hidalgo Medina exercised stock options for 950 shares on August 5, 2026 at an exercise price of $32.5500 per share, receiving 950 common shares. He then sold 1,700 common shares in two trades at $163.9450 and $164.6051 per share. After the exercise, he continued to hold stock options covering 12,079 shares that were granted on July 17, 2024 and vest 25% on July 17, 2025, with the remaining 75% vesting monthly over the following three years.
Guardant Health, Inc. director Ian T. Clark exercised stock options and sold shares held through a family trust. On 2026-08-04, options for 2,255 and 6,833 shares of common stock were exercised at strike prices of $91.11 and $50.57. The Thornton-Clark Family Trust then sold a total of 14,180 common shares at weighted average prices of $158.98 and $158.80, within disclosed price ranges.
Manuel Hidalgo Medina filed to sell up to 1,700 shares of Guardant Health, Inc. common stock through Charles Schwab & Co., Inc., to be traded on NASDAQ. The filing lists upcoming share availability from restricted stock lapses and an employee stock option exercise, and notes prior sales of 1,250 and 1,000 shares in the past three months.
Meghan V. Joyce filed a notice relating to potential sales of Guardant Health, Inc. common stock. The filing covers up to 1,803,685 shares to be sold through Charles Schwab & Co., Inc., with an approximate aggregate market value of $134,196,170 and a proposed sale date of 08/05/2026 on NASDAQ.
The notice also lists sales over the prior three months: 10,000 shares for $1,269,809.00 on 06/03/2026, 6,203 shares for $812,604.00 on 06/22/2026, 2,000 shares for $280,045.00 on 06/24/2026, 2,000 shares for $300,082.00 on 06/26/2026, and 4,000 shares for $660,000.00 on 07/01/2026. The securities are described as arising from a restricted stock lapse in connection with equity compensation.
Guardant Health, Inc. insider Ian T. Clark filed notice of a proposed sale of 14,180 shares of common stock, with an aggregate market value of $2,253,450.00, to be sold on or about 08/04/2026 through Charles Schwab & Co., Inc. on NASDAQ. Guardant Health had 134,196,170 shares of common stock outstanding in connection with this notice. During the prior three months, Clark sold 6,876 shares on 05/20/2026 for $735,049.00, and the filing lists planned transactions tied to restricted stock lapse and an employee stock option exercise.
Guardant Health, Inc., a precision oncology company, has filed an automatic shelf registration as a well-known seasoned issuer. The shelf registration allows Guardant to offer from time to time primary securities, including common stock, preferred stock, debt securities, depositary shares, warrants, purchase contracts and units, in one or more offerings. It also registers the resale of shares of common stock held by selling stockholders, and Guardant will not receive proceeds from those resale transactions. Net proceeds from any primary offerings will be used as described in the applicable prospectus supplements. Guardant’s common stock trades on the Nasdaq Global Select Market under the symbol “GH,” and the last reported sale price was $144.07 per share on July 29, 2026. The company is incorporated in Delaware and is a leading provider of blood and tissue tests, real-world data and AI analytics for cancer screening, monitoring and treatment selection.
Guardant Health, Inc. reported rapid top-line growth but continued losses for the three and six months ended June 30, 2026. Q2 revenue was $334,978 (thousands) versus $232,088 (thousands) a year earlier, driven by oncology revenue of $219,105 (thousands) (prior-year $158,685) and screening revenue of $52,866 (thousands) (prior-year $14,814). Net loss for Q2 was $120,142 (thousands), or $0.90 per share, compared with $99,899 (thousands); for the first half, net loss was $232,217 (thousands) on revenue of $636,643 (thousands) versus $435,559 (thousands).
As of June 30, 2026, cash and cash equivalents were $1,053,469 (thousands) and restricted cash was $114,270 (thousands), with no short-term marketable securities, while long-term convertible senior notes had a net carrying amount of $1,502,943 (thousands). Stockholders’ deficit widened to $222,867 (thousands), reflecting an accumulated deficit of $3,226,729 (thousands) and 133.6 million common shares outstanding at quarter-end.
The company describes a broad precision oncology and screening portfolio, including FDA-approved Guardant360 CDx tests and the Shield blood test for colorectal cancer screening, which has FDA approval, Medicare coverage and guideline inclusion. Legal contingencies include a patent verdict in favor of TwinStrand Biosciences and the University of Washington, for which Guardant has recorded an $83.4 million liability and disclosed an estimated possible loss range through June 30, 2026 of zero to $250 million.